Literature DB >> 22475924

Percutaneous biopsy based on PET/CT findings in cancer patients: technique, indications, and results.

Almir G V Bitencourt1, Chiang J Tyng, Paula N V Pinto, Maria Fernanda A Almeida, Livia C Meyrellis, Renata P Pinheiro, Eduardo N P Lima, Rubens Chojniak.   

Abstract

OBJECTIVE: To describe a technique for CT-guided biopsy based on PET/CT findings and to evaluate the indications and results of the technique in cancer patients.
METHODS: We evaluated all patients receiving CT-guided percutaneous biopsies whose indication was based on PET/CT findings at an oncology reference center from October 2009 to December 2010. The PET/CT images were evaluated side by side with noncontrast CT images to identify the lesion or area of interest to be biopsied. Biopsies were guided by CT with the needle directed at the area of metabolic activity identified in the PET/CT examination performed before the procedure.
RESULTS: A total of 64 cases were included in this study. The most common lesion location was pulmonary (n = 28; 43.8%). The median of the lesions' greatest diameter and maximum SUV were 44.1 ± 31.6 mm (10-186 mm) and 8.4 ± 5.9 (2.1-34.0), respectively. The histologic results of the biopsies were negative for malignancy in 15 cases (23.4%), positive in 46 cases (71.9%), and inconclusive in 3 cases (4.7%). Lesions with an SUV ≥ 4.0 were more likely to be malignant (85.4% vs. 46.2%; P = 0.006).
CONCLUSIONS: CT-guided biopsies should be used routinely for lesions identified or better characterized by PET/CT. The results of this study demonstrate that this method is reliable, secure, and very accurate diagnostically, revealing a high percentage of malignant lesions.

Entities:  

Mesh:

Year:  2012        PMID: 22475924     DOI: 10.1097/RLU.0b013e3182443b78

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

1.  Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.

Authors:  F Cornelis; M Silk; H Schoder; H Takaki; J C Durack; J P Erinjeri; C T Sofocleous; R H Siegelbaum; M Maybody; S B Solomon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-09       Impact factor: 9.236

2.  Improving CT-guided transthoracic biopsy of mediastinal lesions by diffusion-weighted magnetic resonance imaging.

Authors:  Marcos Duarte Guimarães; Bruno Hochhegger; Marcelo Felipe Kuperman Benveniste; Bruno Calazans Odisio; Jefferson Luiz Gross; Charles Edouard Zurstrassen; Chiang Cheng Tyng; Almir Galvão Vieira Bitencourt; Edson Marchiori
Journal:  Clinics (Sao Paulo)       Date:  2014-11       Impact factor: 2.365

3.  Computed tomography-guided percutaneous biopsy of bone lesions: rate of diagnostic success and complications.

Authors:  Macello Jose Sampaio Maciel; Chiang Jeng Tyng; Paula Nicole Vieira Pinto Barbosa; Almir Galvão Vieira Bitencourt; João Paulo Kawaoka Matushita Junior; Charles Edouard Zurstrassen; Wu Tu Chung; Rubens Chojniak
Journal:  Radiol Bras       Date:  2014 Sep-Oct

4.  Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma.

Authors:  Alessandro Broccoli; Cristina Nanni; Alberta Cappelli; Francesco Bacci; Alessandro Gasbarrini; Elena Tabacchi; Carlo Piovani; Lisa Argnani; Riccardo Ghermandi; Elena Sabattini; Rita Golfieri; Stefano Fanti; Pier Luigi Zinzani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-15       Impact factor: 9.236

5.  Performance of Ultrasound-Guided Core Biopsy Driven by FDG-avid Supraclavicular Lymph Nodes in Patients With Suspected Lung Cancer.

Authors:  Tongtong Wang; Junbao Liu; Ningning Lv; Shi Xuan; Lin Bai; Bin Ji; Shi Gao
Journal:  Front Med (Lausanne)       Date:  2022-01-20

6.  Functional imaging with diffusion-weighted MRI for lung biopsy planning: initial experience.

Authors:  Marcos D Guimaraes; Edson Marchiori; Bruno C Odisio; Bruno Hochhegger; Almir G V Bitencourt; Charles E Zurstrassen; Chiang C Tyng; Jefferson L Gross; Rubens Chojniak; Myrna C B Godoy
Journal:  World J Surg Oncol       Date:  2014-07-10       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.